Trial intelligence / Profile preview

STARK

2024-518500-47-00Phase 2Authorised

Sponsor: Università di Padova
Start: Jul 2025
Modality: Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
Countries: 1

Overview

Phase 2, randomised trial of atorvastatin and pembrolizumab in triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC) (4 cohorts), sponsored by Università di Padova. Primary endpoints: Change in CD8+/PD-1+ cell density in TNBC tumor tissue and Early ctDNA response in NSCLC. Planned start Jul 2025; status: authorised.

Drugs

atorvastatinpembrolizumab

Conditions

triple-negative breast cancer (TNBC)non-small cell lung cancer (NSCLC)

Beyond the preview

Go deeper on 2024-518500-47-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2024-518500-47-00.